Evaluation of the Fullerene Compound DF-1 As a Radiation Protector

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2010 May 13

PMID 20459795

Citations 7

Authors

Aaron P Brown

Eun Joo Chung

Mary Ellen Urick

William P Shield 3rd

Anastasia L Sowers

Angela Thetford

Uma T Shankavaram

James B Mitchell

Deborah E Citrin

Affiliations

Soon will be listed here.

Abstract

Background: Fullerene compounds are known to possess antioxidant properties, a common property of chemical radioprotectors. DF-1 is a dendrofullerene nanoparticle with antioxidant properties previously found to be radioprotective in a zebrafish model. The purpose of this study was to evaluate the radioprotective effects of DF-1 in a murine model of lethal total body irradiation and to assess for selective radioprotection of normal cells versus tumor cells.

Methods: In vitro radioresponse was evaluated with clonogenic assays with human tumor cells and fibroblast lines in the presence of varying concentrations of DF-1 or vehicle. DNA double strand break induction and repair was evaluated with immunocytochemistry for gammaH2AX. Lethal total body irradiation was delivered with 137Cs after intraperitoneal delivery of DF-1 or vehicle control. Bone marrow hypoxia was evaluated with piminidazole uptake assessed by flow cytometry.

Results: DF-1 provided modest radioprotection of human cancer cell lines and fibroblast cell lines when delivered prior to irradiation (dose modifying factor or 1.1). There was no evidence of selective protection of fibroblasts versus tumor cells. Cells treated with DF-1 at radioprotective doses were found to have fewer gammaH2AX foci at 1 and 6 hours after irradiation compared to vehicle treated controls. The LD50/30 for C57Bl6/Ncr mice treated with a single 300 mg/kg dose of DF-1 pre-irradiation was 10.09 Gy (95% CI 9.58-10.26) versus 8.29 Gy (95% CI, 8.21-8.32) for control mice. No protective effects were seen with a single 200 mg/kg dose. No increase in pimonidazole uptake was appreciated in bone marrow of mice treated with DF-1 compared to vehicle controls.

Conclusions: DF-1 has modest activity as a radiation protector in vivo. There was no evidence of selective protection from irradiation of normal versus tumor cells with DF-1.

Citing Articles

Bioresponsive Nanomaterials: Recent Advances in Cancer Multimodal Imaging and Imaging-Guided Therapy.

Zeng Z, Gao H, Chen C, Xiao L, Zhang K Front Chem. 2022; 10:881812.

PMID: 35372260 PMC: 8971282. DOI: 10.3389/fchem.2022.881812.

Radioprotective Effect of Beta D-Glucan and Vitamin E on Gamma Irradiated Mouse.

Tabeie F, Tabatabaei S, Mahmoud-Pashazadeh A, Assadi M J Clin Diagn Res. 2017; 11(2):TC08-TC11.

PMID: 28384957 PMC: 5376888. DOI: 10.7860/JCDR/2017/19367.9437.

Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion.

Dimri M, Joshi J, Chakrabarti R, Sehgal N, Sureshbabu A, Kumar I Zebrafish. 2014; 12(1):33-47.

PMID: 25517940 PMC: 4298150. DOI: 10.1089/zeb.2014.0992.

Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation.

Chatterjee D, Wolfe T, Lee J, Brown A, Singh P, Bhattarai S Transl Cancer Res. 2014; 2(4):256-268.

PMID: 25279336 PMC: 4179207. DOI: 10.3978/j.issn.2218-676X.2013.08.10.

Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.

Rodgers K, Espinoza T, Roda N, Meeks C, Hill C, Louie S Int J Radiat Biol. 2012; 88(6):466-76.

PMID: 22433112 PMC: 6421841. DOI: 10.3109/09553002.2012.676228.

References

Bonnaud S, Niaudet C, Pottier G, Gaugler M, Millour J, Barbet J . Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res. 2007; 67(4):1803-11. DOI: 10.1158/0008-5472.CAN-06-2802. View

Dugan L, Lovett E, Quick K, Lotharius J, Lin T, OMalley K . Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 2001; 7(3):243-246. DOI: 10.1016/s1353-8020(00)00064-x. View

Walden Jr T, Sawich C . Induction of marrow hypoxia by radioprotective agents. Radiat Res. 1989; 118(3):581-6. View

Hahn S, Wilson L, Krishna C, Liebmann J, DeGraff W, Gamson J . Identification of nitroxide radioprotectors. Radiat Res. 1992; 132(1):87-93. View

Davidson W, Ren Q, Kari G, Kashi O, Dicker A, Rodeck U . Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle. 2008; 7(9):1224-30. DOI: 10.4161/cc.7.9.5786. View

Vos O, BUDKE L, Grant G . In vitro evaluation of some latent radioprotective compounds. Int J Radiat Biol Relat Stud Phys Chem Med. 1976; 30(5):433-48. DOI: 10.1080/09553007614551251. View

Horie M, Fukuhara A, Saito Y, Yoshida Y, Sato H, Ohi H . Antioxidant action of sugar-pendant C60 fullerenes. Bioorg Med Chem Lett. 2009; 19(20):5902-4. DOI: 10.1016/j.bmcl.2009.08.067. View

Ghosh S, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao T . Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol. 2009; 85(7):598-606. DOI: 10.1080/09553000902985128. View

Ghosh S, Perkins M, Hieber K, Kulkarni S, Kao T, Reddy E . Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res. 2009; 171(2):173-9. DOI: 10.1667/RR1367.1. View

10.

Yuhas J . Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat Res. 1970; 44(3):621-8. View

11.

Soule B, Hyodo F, Matsumoto K, Simone N, Cook J, Krishna M . The chemistry and biology of nitroxide compounds. Free Radic Biol Med. 2007; 42(11):1632-50. PMC: 1991293. DOI: 10.1016/j.freeradbiomed.2007.02.030. View

12.

Nielsen G, Roursgaard M, Jensen K, Poulsen S, Larsen S . In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol. 2008; 103(3):197-208. DOI: 10.1111/j.1742-7843.2008.00266.x. View

13.

Utley J, Marlowe C, Waddell W . Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2. Radiat Res. 1976; 68(2):284-91. View

14.

Lin H, Lin T, Lai R, DRosario T, LUH T . Fullerenes as a new class of radioprotectors. Int J Radiat Biol. 2001; 77(2):235-9. DOI: 10.1080/095530001750068966. View

15.

Trajkovic S, Dobric S, Jacevic V, Dragojevic-Simic V, Milovanovic Z, Dordevic A . Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats. Colloids Surf B Biointerfaces. 2007; 58(1):39-43. DOI: 10.1016/j.colsurfb.2007.01.005. View

16.

Ryman-Rasmussen J, Tewksbury E, Moss O, Cesta M, Wong B, Bonner J . Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol. 2008; 40(3):349-58. PMC: 2645533. DOI: 10.1165/rcmb.2008-0276OC. View

17.

Dumont F, Le Roux A, Bischoff P . Radiation countermeasure agents: an update. Expert Opin Ther Pat. 2009; 20(1):73-101. DOI: 10.1517/13543770903490429. View

18.

Lao F, Li W, Han D, Qu Y, Liu Y, Zhao Y . Fullerene derivatives protect endothelial cells against NO-induced damage. Nanotechnology. 2009; 20(22):225103. DOI: 10.1088/0957-4484/20/22/225103. View

19.

Lucente-Schultz R, Moore V, Leonard A, Price B, Kosynkin D, Lu M . Antioxidant single-walled carbon nanotubes. J Am Chem Soc. 2009; 131(11):3934-41. DOI: 10.1021/ja805721p. View

20.

Mitchell J, DeGraff W, Kaufman D, Krishna M, Samuni A, Finkelstein E . Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys. 1991; 289(1):62-70. DOI: 10.1016/0003-9861(91)90442-l. View